Literature DB >> 1593693

A 20-year experience with treatment of ectopic ureteroceles.

Y Mor1, J Ramon, G Raviv, P Jonas, B Goldwasser.   

Abstract

Between 1970 and 1990 a total of 37 patients (female-to-male ratio 3.6:1) was diagnosed and treated at our institution for ectopic ureterocele. Urinary tract infection was the most frequent mode of presentation (59%). Of the patients 54% were less than 3 years old at operation. Transurethral incision of ectopic ureterocele served only as a decompressive procedure for acutely ill infants and was followed with a high incidence (80%) of resultant vesicoureteral reflux. The elective surgical policy was individualized based on renal function and presence of vesicoureteral reflux. Overall results within the various groups were generally satisfactory regarding eradication of urinary tract infections, preservation of renal function and continence or treatment of vesicoureteral reflux. Upper pole heminephrectomy and partial ureterectomy were performed in 14 patients with 3 (21%) requiring reoperation, including only 2 (14%) subsequent reimplantations. Thus, we believe that an expectant approach to the lower urinary tract is well recommended in the majority of the patients with a poorly functioning ipsilateral renal segment. A modified technique of total reconstruction, performing only partial ureterectomy with double barrel reimplantation, was successful in 7 patients.

Entities:  

Mesh:

Year:  1992        PMID: 1593693     DOI: 10.1016/s0022-5347(17)37637-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  39-year-old man with voiding symptoms.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2004

2.  Does endoscopic puncture of ureterocele provide not only an initial solution, but also a definitive treatment in all children? Over the 26 years of experience.

Authors:  Jaber Jawdat; Shachar Rotem; Stanislav Kocherov; Amicur Farkas; Boris Chertin
Journal:  Pediatr Surg Int       Date:  2018-03-29       Impact factor: 1.827

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.